Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) Gross Profit (2017 - 2025)

Organogenesis Holdings has reported Gross Profit over the past 9 years, most recently at $98.6 million for Q4 2025.

  • Quarterly results put Gross Profit at $98.6 million for Q4 2025, up 3.17% from a year ago — trailing twelve months through Dec 2025 was $349.6 million (down 4.56% YoY), and the annual figure for FY2025 was $349.6 million, down 4.56%.
  • Gross Profit for Q4 2025 was $98.6 million at Organogenesis Holdings, down from $114.6 million in the prior quarter.
  • Over the last five years, Gross Profit for ORGO hit a ceiling of $114.6 million in Q3 2025 and a floor of $63.0 million in Q1 2025.
  • Median Gross Profit over the past 5 years was $88.4 million (2022), compared with a mean of $87.1 million.
  • Biggest five-year swings in Gross Profit: skyrocketed 90.64% in 2021 and later dropped 27.38% in 2025.
  • Organogenesis Holdings' Gross Profit stood at $95.3 million in 2021, then decreased by 7.2% to $88.4 million in 2022, then decreased by 18.69% to $71.9 million in 2023, then skyrocketed by 33.0% to $95.6 million in 2024, then rose by 3.17% to $98.6 million in 2025.
  • The last three reported values for Gross Profit were $98.6 million (Q4 2025), $114.6 million (Q3 2025), and $73.4 million (Q2 2025) per Business Quant data.